Altimmune Inc
3G0
Company Profile
Business description
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Several gaming shares are trading at a discount to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.00 | 82.40 | -0.92% |
| CAC 40 | 8,146.83 | 69.95 | -0.85% |
| DAX 40 | 25,736.24 | 309.13 | -1.19% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,551.17 | 138.70 | -1.30% |
| HKSE | 23,294.75 | 213.42 | -0.91% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,522.52 | 498.24 | 0.84% |
| NZX 50 Index | 14,237.35 | 26.94 | -0.19% |
| S&P 500 | 7,323.63 | 16.90 | -0.23% |
| S&P/ASX 200 | 8,740.30 | 81.50 | -0.92% |
| SSE Composite Index | 3,587.80 | 0.03 | -0.00% |